Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Diabetic Macular Edema Treated with Anti–Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{3cc1310560e8451fb88838dee3407626,
title = "Diabetic Macular Edema Treated with Anti–Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers",
abstract = "Purpose To investigate central subfield thickness (CST) nonimprovers{\textquoteright} anatomic response in macular areas outside the central subfield and the time course of this response. Furthermore, to investigate the relationship between peripheral improvement and visual acuity. Design Retrospective study. Participants A total of 566 eyes in 566 patients with center-involved diabetic macular edema who initiated intravitreal treatment with ranibizumab between January 1, 2011 and December 31, 2013 in the Greater Copenhagen Region. Follow-up was completed at 2 years. Methods Patients were initially grouped as CST improvers and CST nonimprovers. The CST improvers had a ≥10% reduction in CST on ≥1 visit as opposed to CST nonimprovers with ",
author = "Delila Hodzic-Hadzibegovic and Sander, {Birgit Agnes} and Marianne Valerius and Henrik Lund-Andersen",
year = "2018",
month = nov,
doi = "10.1016/j.oret.2018.04.026",
language = "English",
volume = "2",
pages = "1133--1142",
journal = "Ophthalmology Retina",
issn = "2468-7219",
publisher = "Elsevier Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Diabetic Macular Edema Treated with Anti–Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers

AU - Hodzic-Hadzibegovic, Delila

AU - Sander, Birgit Agnes

AU - Valerius, Marianne

AU - Lund-Andersen, Henrik

PY - 2018/11

Y1 - 2018/11

N2 - Purpose To investigate central subfield thickness (CST) nonimprovers’ anatomic response in macular areas outside the central subfield and the time course of this response. Furthermore, to investigate the relationship between peripheral improvement and visual acuity. Design Retrospective study. Participants A total of 566 eyes in 566 patients with center-involved diabetic macular edema who initiated intravitreal treatment with ranibizumab between January 1, 2011 and December 31, 2013 in the Greater Copenhagen Region. Follow-up was completed at 2 years. Methods Patients were initially grouped as CST improvers and CST nonimprovers. The CST improvers had a ≥10% reduction in CST on ≥1 visit as opposed to CST nonimprovers with

AB - Purpose To investigate central subfield thickness (CST) nonimprovers’ anatomic response in macular areas outside the central subfield and the time course of this response. Furthermore, to investigate the relationship between peripheral improvement and visual acuity. Design Retrospective study. Participants A total of 566 eyes in 566 patients with center-involved diabetic macular edema who initiated intravitreal treatment with ranibizumab between January 1, 2011 and December 31, 2013 in the Greater Copenhagen Region. Follow-up was completed at 2 years. Methods Patients were initially grouped as CST improvers and CST nonimprovers. The CST improvers had a ≥10% reduction in CST on ≥1 visit as opposed to CST nonimprovers with

U2 - 10.1016/j.oret.2018.04.026

DO - 10.1016/j.oret.2018.04.026

M3 - Journal article

C2 - 31047551

VL - 2

SP - 1133

EP - 1142

JO - Ophthalmology Retina

JF - Ophthalmology Retina

SN - 2468-7219

IS - 11

ER -

ID: 55656624